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ABSTRACT 
The presence of psychosis is associated with more rapid decline in Alzheimer’s disease (AD), but the 
impact of paranoid (persecutory delusions) and misidentification (misperceptions and/or 
hallucinations) subtypes of psychosis on the speed of decline in AD is still unclear. Here we analysed 
data on Alzheimer’s Disease Neuroimaging Initiative (ADNI)2  participants with late mild cognitive 
impairment or AD and we described individual trajectories of Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (ADAS-cog) scores using a semi-mechanistic, logistic model, with a mixed 
effects based approach, which accounted for drop-out, and adjusted for baseline Mini Mental State 
Examination scores. The covariate model included psychosis subtypes, age, gender, education, 
medications and Apo-e ε4 genotype. We found that ADAS-cog rate of increase was doubled in 
misidentification (r,misid_subtype=0.63, p=0.031) and mixed (both subtypes) ((r,mixed_subtype=0.70, 
p=0.003) compared to non-psychotic (or paranoid) subjects suggesting that the misidentification 
subtype may represent a distinct AD sub-phenotype associated with an accelerated pathological 
process.  
 
INTRODUCTION 
Psychosis symptoms (delusions, hallucinations) are common in Alzheimer’s disease (AD)1 and 
manifest early in the illness course. They are associated with an accelerated speed of cognitive and 
functional decline and precipitate earlier institutionalisation2. Research which aims to elucidate the 
pathophysiology of AD psychosis and its relationship with disease progression could help to direct 
future treatment strategies. Factor analysis of AD psychosis symptoms has identified two broad 
categories: a “paranoid” subtype, characterised by delusions of theft, harm and abandonment, and a 
“misidentification” subtype, comprised of misperceptions, misidentification delusions, and visual or 
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auditory hallucinations3,4. Studies which have investigated the phenotypic aspects of AD psychosis 
subtypes have reported greater performance deficits on tests of visual sustained attention and 
visuoperceptual function5, reduced volume in functional networks involved in perception and context 
based recognition of visual stimuli6,7 and greater hippocampal/limbic pathology at post-mortem8,9,10, 
but only in association with the misidentification subtype. It is unclear whether AD psychosis 
subtypes are part of the same biological continuum 3,4 with misperceptions emerging later in the AD 
process 4,11 or whether the two subtypes have distinct disease course trajectories.  
This study aimed to investigate longitudinal data from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) with the following objectives: 
1) To describe the trajectory of cognitive decline, indexed by the rate of increase in Alzheimer’s 
Disease Assessment Scale-Cognitive Subscale (ADAS-cog)12 scores, in early AD, using a 
mixed effects based approach13. 
2) To test the hypothesis that the misidentification subtype would be associated with a faster rate 
of cognitive decline. 
 
METHODS  
Participants   
Data were obtained from ADNI, a multicentre longitudinal study which collected clinical, 
neuroimaging, neuropsychological and blood/cerebrospinal, data from healthy controls (HC), and 
those with both mild cognitive impairment (MCI) and early AD, with the aim of identifying markers 
of AD progression (adni-info.org). MCI was classified as early (EMCI) and late MCI (LMCI) based 
on a cut off for objective memory impairment determined using the Wechsler Memory Scale Logical 
Memory II (adni.loni.usc.edu). Data of interest (downloaded 18th January, 2016) included all 
participants diagnosed with AD and LMCI at baseline and those who developed MCI and AD over 
the observation period, but excluded those who subsequently reverted to HC or ECMI as they did not 
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show a cognitive decline over the time accordingly to AD NIA-AA criteria.14 The analysis was 
restricted to ADNI2 participants, as full Neuropsychiatric Inventory (NPI)15 data (which was not 
included in earlier phases of ADNI) was required to assign subtype3,4,5. Participants were coded as 
“psychotic” if symptoms were coded as present (scores of 1 or more on delusions or hallucinations 
domains) either at baseline or any follow-up visit. The paranoid subtype included items 1,2,3,7 from 
the delusions domain (“In danger/others are planning to hurt him or her”, “Others are stealing from 
him or her”, “Spouse is having an affair”, “Family members plan to abandon him or her”); the 
misidentification subtype included items 4,5,6,8 from the delusions domain (“Unwelcome guests are 
staying in his or her house“, “His or her spouse or others are not who they claim to be”, “His or her 
house is not his or her own”, “Television/magazine figures are present in his or her home”) and items 
1,2,3 from the hallucinations domain (“He or she can hear voices”, “Talks to people who are not 
there”, “Seeing things not seen by others”); those who were coded positive on items from both 
paranoid and misidentification symptoms were described as “mixed”; and non-psychotic phenotype 
was assigned if no items were coded positive at any of the visits. Cognitive and functional status were 
measured using ADAS-cog, Mini Mental State Examination (MMSE)16, Clinical Dementia Rating 
scale (CDR)17 and Functional Activities Questionnaire (FAQ)18 scores. Assessments were carried out 
at baseline, 6 months, 12 months and annually thereafter. The longest observation period was 4 years, 
corresponding to a baseline and 4 or 5 follow-up visits.  Between-AD and psychosis subtypes 
differences for age, gender, education, Apo-e ε4 genotype, MMSE, CDR, FAQ, ADAS-cog and NPI 
total score at baseline were analysed using chi-squared tests and Analysis of Variance (ANOVA).  
Data collection and sharing in ADNI were approved by the Institutional Review Board of each 
participating institution, and written informed consent was obtained from all participants.  
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ADAS-cog score trajectory model 
The non-linear trajectory of cognitive decline was described using the general logistic function model 
(an equation based on Richard’s function)19,20,21 below: 
            
             
                                           
 
 The model comprised three parameters:  Baseline ADAS-cog scores (ADAS-cog0); rate (slope) of 
increase in ADAS-cog scores (r); and a shape parameter ( which controls an inflection point in the 
trajectory, beyond which rate of decline slows. Higher values of r and  indicate faster cognitive 
decline and steeper trajectory respectively.  
Non-linear mixed effects (NLME) modelling was used to explore sources of variability in the 
trajectory of decline separating inter-individual variability (IIV) and residual unexplained variability 
(RUV)13. Inter-individual random effects and residual unexplained errors were assumed to be 
independent. A log transformation of the observations ADAS-cogij of subject i at time tij and model 
predictions                                was used to ensure positivity and we used an 
additive error model as follows: 
                                                         
This allows the standard deviation   of the residual errors    , which follow a Gaussian, to be 
expressed as a coefficient of variation on predicted ADAS-cog scores. 
Inter-individual random effects were estimated on ADAS-cog0, r and A probit-normal 
transformation was used for ADAS-cog0 to ensure predicted individual values were between 0 and 
70, as follows: 
            
                           
With        the population value for ADAS-cog0,  
   the inverse cumulative distribution function 
(quantile function) associated with the standard normal distribution N(0,1) and            following 
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a normal distribution of mean 0 and standard deviation             
For r and , a log-normal transformation was used to ensure positivity, as follows: 
      
    
      
    
With    and    the population value for r and  , respectively and     qnd     following normal 
distributions of mean 0 and standard deviations    and   , respectively. All covariate-parameter 
associations were modelled using a linear regression on the random effect scale e.g.: 
      
               
With covi, the value for the covariate of interest for subject i and        the effect coefficient of cov on 
parameter r. Paranoid, misidentification and mixed subtypes were each compared to non-psychotic 
phenotype and other covariates previously shown to have an effect on disease progression parameters 
(baseline age, baseline MMSE score, gender, education, presence of Apo-e ε4 alleles, age, baseline 
use of cognitive enhancers)20,21 were tested on parameters ADAS-cog0 and r with a Wald test at level 
0.05. Continuous covariates were centred on the mean, and gender, Apo-e ε4 genotype and use of 
cognitive enhancers were encoded as categorical covariates; with “male gender”, “not being a carrier 
of Apo-e ε4” and “no medication” used as reference values. 
Drop out model  
A Survival (time to event) model was used to fit attrition rate, using a Weibull baseline hazard 
function22       as risk was expected to change over time. This model includes a shape parameter, k 
which, when greater than 1, indicates an increase in attrition rate over time, when equal to 1 that 
attrition is constant over time (such as in the exponential model), and when less than 1 that the 
attrition rate decreases with time; and a scale factor , with 1/ corresponding to the mean time before 
drop out if k is equal to 1:  
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An effect of the current predicted ADAS-cog score was tested on the hazard function of drop-out, h(t) 
as follows: 
         
                                             
With            the effect coefficient of the unobserved ADAS-cog score value on the risk of drop-
out, corresponding to a missing not at random mechanism.  
Drop out and ADAS-cog models were jointly estimated.  
 
Model evaluation and predictions 
Model parameters were estimated using the Stochastic Approximation to the Expectation 
Maximization algorithm 23. Appropriateness of base and covariate models were evaluated using 
goodness-of-fit plots (e.g. visual predictive check (VPC)) and metrics, (standard errors and Bayesian 
information criteria (BIC)).  
Parameter fixed effect estimates were used to plot typical ADAS-cog trajectories for each subtype, 
accounting for other significant covariate effects.  
 
Softwares 
Demographic and clinical data were analysed using SPSS 23(www.spss.com). The data set was 
prepared using R (version 3.2.1) and the Monolix software was used for model fit and evaluation 
(version 2016 R1; www.lixoft.eu). 
 
RESULTS 
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Demographic and clinical characteristics  
ADAS-cog trajectories from 528 participants are shown in spaghetti plots in figure 1 on the natural 
(A) and on the log scale (B). In median, patients attended 3 visits ranging from 1 to 6 visits over 4 
years (total 1783 observations). Demographic information about the subjects is summarized in Table 
1. The sample consisted of 212 AD, 239 LMCI and 29 EMCI subjects at baseline. Forty-eight HC 
converted to LMCI or AD over the observation period. Attrition rate was high (92%), with only 42 
participants remaining at the final follow-up visit (year 4). Possible explanations for the high attrition 
are the i) worsening of cognitive and functional impairment of the patients (tested via the effect of 
predicted current ADAS-cog scores on the hazard of drop-out), ii) the occurrence of an age-related 
disease and iii) death. Of note, vital status was not informed in the ADNI2 data set. There were 96 
patients with psychosis symptoms (38 paranoid, 29 misidentification, and 29 mixed), who did not 
differ significantly from non-psychotic patients in terms of age, and education (Table 1). At baseline 
there were 38 patients with psychosis, 33 patients developed psychosis at 1st follow-up visit, 17 
patients at 2nd follow-up visit, 7 at 3rd follow-up visit and 1 at 4th follow-up visit. A gender 
difference was found across psychotic status (62% male non psychotic vs. 61% paranoid vs. 38% 
Misid. vs 48% mixed). Participants with psychosis symptoms were more cognitively and functionally 
impaired than non-psychotic patients at baseline (see cognitive and functional scores mean (± SD) in 
Table 1 and Figure 2). In post-hoc analyses on the basis of subtype, only the mixed subtype had 
significantly higher baseline ADAS-cog scores (p=0.001) and lower baseline MMSE scores (p=0.001) 
compared to the non-psychotic group; whereas the mixed and misidentification subtypes had 
significantly higher baseline CDR (p=0.042 and p<0.001, respectively) compared to the non-
psychotic group (Figure 2).  
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ADAS-cog trajectory model 
Baseline Model 
Parameter estimates for the base model (without covariates) and for the final model (including 
covariates) are shown in Table 2. The final model estimated an inflection point when ADAS-cog 
scores reached 38.2 with 95% confidence interval=[32.9-41.8], beyond which rate of decline slows.  
 
Covariate model 
The paranoid subtype was found to have an estimate of the rate of progression not significantly 
different from the non-psychotic subtype, therefore paranoid and non-psychotic subtypes were 
combined in a reference subtype in the following analyses. Compared to this reference subtype, 
misidentification, and mixed subtypes had significantly higher estimates of the rate of progression 
(multiplied by a factor 1.87 and 2 with p<0.031 and <0.003, respectively).  
The presence of at least one allele of Apo-e 4 gene was found to double the rate of progression 
(p<0.001), leading to a rate of progression fourfold higher in patients having at least one Apo-e ε4 
allele and being categorised into the misidentification or mixed subtypes. A significant effect of 
baseline MMSE score was found on the parameter ADAS-cog0 (p<0.001) with an ADAS-cog0 of 
7.02 associated to a MMSE score of 30 and an ADAS-cog0 of 57.50 for a MMSE score of 6, 
accounting for the association between ADAS-cog0 and MMSE score at baseline lowered the IIV 
estimates on ADAS-cog0 by 40%. 
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Drop out model 
The k parameter was estimated greater than 1 (2.03) confirming that drop-out hazard rate increases 
with time.  The current predicted ADAS-cog score was found to significantly increase the drop-out 
hazard, with a drop-out hazard rate at 12 months 5 times higher for those with an ADAS-cog score of 
50 compared to those with a score of 13 (βh0,ADAS-cog =0.04, p <0.001). 
 
Model evaluation  
Visual predictive checks (VPC) on log-transformed ADAS-cog scores are shown in Figure 1 C. 
Observed percentiles are adequately included in the predicted bands from model simulations, but on 
one occasion for the median and upper band and on two occasions for the lower band. Further 
goodness of fit plots are provided in the supplementary material along with the mlxtran code and the 
data set. 
 
Model predictions 
Model fixed effect estimates were used to plot the ADAS-cog trajectory for a typical patient from 
each of the following categories: baseline MMSE score of 10, 25 or 29; non-psychotic (or paranoid), 
misidentification and mixed subtypes; non-carrier (Figure 3A) or carrier (Figure 3B) of at least one 
Apo-e ε4 allele. 
 
DISCUSSION 
This study investigated the impact of psychosis subtype on the rate of disease progression/cognitive 
decline in AD, using a semi-mechanistic model to describe the trajectory of change in ADAS-cog 
scores. In line with our hypothesis, the misidentification subtype (alone or as part of a mixed subtype) 
was associated with an increased rate of decline compared to non-psychotic or paranoid subtype. 
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These findings were not explained by differences in baseline cognitive status in those who presented 
solely with misidentifications, as ADAS-cog (and MMSE) were similar across paranoid, 
misidentification and non-psychotic group, with only the mixed subtype being more impaired at 
baseline.  
Faster rate of decline in misidentification subtype might be associated with earlier and greater 
pathological change in functional networks involved in perception, recognition of visual stimuli. 
Indeed previous studies evidenced in patients with misidentification subtype poorer performance on 
neuropsychological tests, which localise to the ventral visual stream5, and greater volume loss in 
functionally connected regions6 including the parahippocampal gyrus, which is involved in the 
processing and retrieval of contextual memories24,25.  There is also evidence of greater neurofibrillary 
tangle burden in frontal26 and limbic/paralimbic regions including the parahippocampal gyrus8,9,26 in 
AD patients with a history of misidentifications and/or hallucinations. Our findings, supported from 
those of previous studies, suggest that the misidentification subtype may be a distinct sub-phenotype 
of AD, and one which is associated with an accelerated cognitive decline.  
The greater proportion of women in the misidentification subtype warrants further discussion, as 
psychosis occurs more frequently in women and histopathologic studies have shown higher levels of 
phosphorylated tau in the frontal cortex of females with AD psychosis compared to their male 
couterparts27. However, when gender was incorporated into the model during covariate testing, we 
could not estimate a significant impact on the ‘rate of progression’ parameter. The presence of at least 
one Apo-e 4 allele increased the rate of cognitive decline in all groups. The effect of the presence of 
Apo-e ε4 on the rate of disease progression has been already demonstrated in previous AD 
progression models20,21,28 but, here, in contrast to Conrado et al. we did not distinguish between the 
presence of one or two alleles. The effect of Apo-e ε4 genotype on rate of decline further supports the 
suggestion that misidentification subtype have a greater neuropathological burden, as Apo-e ε4 is 
involved in the deposition of both neurofibrillary tangles and amyloid29 and regulates A 
clearance30,31. We found an effect of MMSE scores at baseline on ADAS-cog0, as showed by Ito et 
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al.; MMSE values are highly correlated to ADAS-cog values and this could explain the improved 
model fit28. 
There were several study limitations. ADNI represents a highly selective dataset, which includes very 
mildly impaired subjects, with high educational attainment, and low vascular burden. As a result of 
mild baseline severity, cognition declined slowly over the 4-year observation period, which meant 
that it was not possible to fully capture the nonlinear trajectory of decline, as managed in previous 
studies19,20 and our decision to use a nonlinear model was essentially based on its superiority over a 
linear model in a previous comparative study20,21.  
It is possible that the absence of differences in rate of decline between paranoid and non-psychotic 
groups reflects poor sensitivity of the ADAS-cog to detect deficits in fronto-executive functioning 
(subscales largely focus on memory, language, visuospatial and praxis functions)32 which are perhaps 
most relevant to the paranoid subtype4. This could be investigated in future analyses, using a similar 
(mixed effects) based approach to describe changes in digit span; a measure of fronto-executive 
function previously shown to decline more rapidly in those with psychosis in previous analyses of 
ADNI data33. Neither can we completely rule out an effect of gender, given the relatively small 
sample size of psychotic subtypes, and this needs to be explored in a larger sample. 
The majority of researchers who have investigated subtype dependency have reported lower MMSE 
scores in those with the misidentification subtype4,11,34, although this has not been consistently 
shown5,6.  In ADNI2 participants, only the mixed group were more impaired, using ADAS-cog and 
MMSE as markers of cognitive status and disease stage. However, all subtypes were impaired in 
functional activities compared to the non-psychotic group, and it will be important to investigate this 
further in future studies, as it is possible that specific functional domains may be more sensitive 
markers of psychosis symptoms.  
All patients diagnosed AD or LMCI during the follow up period were included in the study. However, 
many of the participants were in the early stages of dementia, or still diagnosed with MCI, and they 
would not have progressed far enough through their illness by the end of the 4 years’ follow-up period 
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to develop psychotic symptoms. It is thus possible that they were assigned a false-negative psychosis 
phenotype.  
The decision to not use a threshold cut-off for NPI scores to define the presence of delusions or 
hallucinations was based on our previous approach5,6 and our aim to examine psychosis ‘trait’ as 
opposed to ‘state’. However this approach increases the risk of false positives.  
The fact that ADNI2 excluded people who had psychotic symptoms within the previous three months, 
or those prescribed antipsychotic or sedative medication, limited the sample size of the psychotic 
group and reduced the power of the study to compare subtypes, or to establish any correlation 
between symptom severity (or antipsychotic use) and cognitive trajectory. Neither was it possible to 
determine the individual contributions of misidentification phenomena and hallucinations to subtype 
specific differences in rate of decline, as the majority of participants had visual and/or auditory 
hallucinations (n=20), with a smaller number having misidentification delusions (n=6) or both (n=3).   
We cannot rule out the possibility that a proportion of ADNI2 participants assigned to the 
misidentification subtype represent undiagnosed cases of Lewy body disease (DLB), given the 
occurrence of visual hallucinations and misidentifications at a relatively mild stage of disease26. 
However post-mortem studies have shown that the early occurrence of these symptoms may also 
represent a greater expression of AD-related pathology26.  
Given the relatively small sample size of each subtype, our findings should be viewed as preliminary 
and investigated prospectively in future studies. The development of positron emission tomography 
ligands which bind to tau and -synuclein35,36 means that it is now possible to simultaneously collect 
clinical (psychosis subtype, neuropsychological test performance), molecular (pathological, 
neurochemical), morphological and functional information in vivo. This approach could be used to 
further elucidate the pathophysiology of the psychosis subtypes in early AD and other 
neurodegenerative disorders (DLB, Parkinson’s disease psychosis) in which the misidentification 
subtype is highly prevalent.  
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Study highlights:  
What is the current knowledge on the topic? 
 
The psychosis phenotype in Alzheimer disease (AD) predicts an accelerated speed of cognitive and 
functional decline, but it is unclear if phenomenological differences in psychosis subtypes have 
distinct disease trajectories.  
 
What question did this study address? 
 
Does the presence of paranoid (persecutory delusions) or misidentification (misperceptions and/or 
hallucinations) subtypes of psychosis have an impact on the speed of cognitive decline in early AD. 
 
What does this study add to our knowledge? 
The misidentification subtype (alone or in conjunction with paranoid delusions) is associated with a 
faster speed of AD progression. These findings may reflect additional AD (or other) pathology in 
functional networks that are involved in the perception and contextual association of visual stimuli. 
 
How might this change drug discovery, development, and/or therapeutics? 
These findings suggest that treatment approaches addressed to AD patients with misidentification 
psychotic subtype, should aim to target functional networks involved in the processing of sensory 
stimuli, to improve psychotic symptoms and to slow down the rate of disease progression.  
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Figure Legends 
 
Figure 1 Individual ADAS-cog scores trajectories over time of patients included in the 
ADNI2 data set on the natural (A) and log (B) scale and visual predictive check of the final 
covariate model of ADAS-cog scores trajectories over time on the log scale (C). The shaded 
areas correspond to the 95% confidence intervals around the 5th and 50th and 95th model 
predicted percentiles and the solid lines correspond to 5th, 50th and 95th percentiles of observed 
data. 
 
Figure 2 Box Plots of Mini Mental State Examination (MMSE) (A), Alzheimer’s Disease 
Assessment Scale-Cognitive Subscale (ADAS-cog) (B), Clinical Dementia Rating scale 
(CDR) (C), Functional Activities Questionnaire FAQ (D), Neuropsychiatric Inventory (NPI) 
(E) scores at baseline in non-psychotic AD and in each psychotic AD subtype (Paranoid, 
Misidentification and mixed).  Overall comparison was performed using Analysis of Variance 
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(ANOVA). Black lines indicate post-hoc pairwise comparisons of interest and * indicates 
significant difference (p <0.05).  
 
Figure 3 Typical ADAS-cog trajectories over 20 years (using model parameter fixed effect 
estimates) for the non-psychotic or paranoid subtype (left), misidentification subtype (centre) 
and mixed (right) subtype for a non-carrier (A) and a carrier (B) of at least one Apo-e  4 
allele. The black, green and red lines correspond to a MMSE score at baseline of 25, 29 and 
10, respectively. Vertical lines represent the end of the follow-up in the current study i.e. 4 
years after inclusion. 
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Misid. misidentification; df degrees of freedom; n.s. non significant; ADAS-cog :Alzheimer’s Disease  
Assessment Scale-Cognitive Subscale ; MMSE: Mini Mental State Examination;NPI: Neuropsychiatric 
Inventory; n.s.; non significant;  CDR: Clinical Dementia Rating scale ; FAQ :Functional Activities 
Questionnaire  
  
Table 1. Demographic and clinical characteristics at baseline (n=528) 
 
 Non Psychotic 
(n=432) 
Paranoid 
(n=39) 
Misid.  
(n=29) 
Mixed 
(n=29) 
Test      df      p value 
Mean (± SD)      
Age  in years 75.9 (±7.9) 76 (±7.2) 74.3 (±8.3) 74.3 (±8.3)  F=0.4         3            0.734 
Education in years 16 (±2.7) 15.9(±2.8) 15.1(±2.4) 16.1(±2.9) F=0.9         3            0.421 
ADAS-cog  14.4 (±8.7) 16.9 (±7.8) 17.6 (±9.9) 20.8 (±9.9) F=6.2        3           <0.001   
MMSE  25.7 (±3.9) 24.6 (±3.2) 24.1 (±5.6) 22.7 (±4.3) F=6.5        3          <0.001 
NPI  5.4 (±7.1) 12 (±10.8)  10.1 (±9.6)  14.6(±12.6) F=21         3          <0.001  
CDR  0.6 (±0.3) 0.7 (±0.3) 0.8 (±0.5) 1 (±0.5) F=11.8      3          <0.001   
FAQ 7.1 (±7.7) 11.4 (±7.6)  13.2(±8.6)  17.1 (±8.2)  F=21.2      3          <0.001 
      
Number (%)      
Gender “Male” 267(62) 24 (61) 11 (38) 14 (48) X2=8.3         3             0.04 
Apo-e 4 non-carrier  208 (48) 10 (25) 11 (38) 8 (27) X2=11.7       3       <0.001 
Cognitive enhancer not prescribed 379 (88) 32 (82)  21 (72)  24 (83)  X2=6.4          3          0.092  
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Table 2 Parameter estimates, relative standard errors (RSE in %) and 95% confidence intervals (95CI) 
for models of cognitive decline trajectory in ADNI2 participants without and with covariates 
 Without covariate With covariate   
        
 Estimate RSE 95%CI Estimate RSE             95%CI p value 
        
ADAS-cog 
trajectory 
model 
       
        
Typical value 
(fixed effects) 
       
        
ADAS-cog0 13.60 3 12.80/14.4
0 
13.80 2 13.26/14.3
4 
 
ADAS-
cog0,MMSE 
ne ne  ne -0.09 4                                -0.10/-0.08  
<0.001 
r 0.14 19 0.09/0.19 0.07 15 0.05/0.09  
r, misid subtype ne  ne ne 0.63 46                              0.06/1.19  
<0.031 
r, mixed subtype ne ne ne 0.70 34                               0.23/1.16  
<0.003 
 r,1 allel Apo-e 4 ne ne ne 0.76 21                               0.45/1.07  
<0.001 
 1.09 46 0.11/2.07 1.54 27 0.73/2.35  
          
IIV        
        
ADAS-cog0 0.42 4 0.39/0.45 0.25 4 0.23/0.27  
r (%) 67 15 47/87 0.66 12 0.50/0.82  
 176 19 110/242 145 14 105/185  
        
RUV        
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ADAS-cog0 :   ADAS-cog score at baseline, r: rate of decline/disease progression, shape parameter 
controlling the inflection point of the decline slope,  ADAS-cog0, MMSE: effect size of baseline MMSE 
score on ADAS-cog0, MMSE score at baseline was centred around the mean,r, misid subtype : effect size 
of misidentification subtype on r, r, mixed subtype:  effect size of mixed subtype on r, misidentification 
and mixed subtype were compared to the reference “non-psychotic (and paranoid)”, r, Allele Apo-e 4 
effect size of Apo-e 4 allele carrier on r, Apo-e  allele carrier status was compared to the reference 
“not carrier”, IIV: inter-individual variability expressed in standard deviation or coefficient of 
variation (%), RUV : residual unexplained variability expressed in coefficient of variation (%), scale 
parameter in the Weibull hazard model, kshape parameter in the Weibull hazard model, h0,ADAS-cog : 
effect of current predicted ADAS-cog score on the baseline hazard, ne : not estimated  
  
        
(%) 26.1 2 25.08/27.1
2 
26 2 25/27  
        
Drop-out 
model 
       
        
Typical 
values (fixed 
effects)
       
        
 4.14 7 3.58/4.70 3.99 5 3.60/4.38  
k 2.02 6 1.79/2.25 2.03 5 1.83/2.23  
 h0,ADAS-cog  0.05 14 0.04/0.06 0.04 10                              0.03/0.05  
<0.001 
        
Bayesian 
Information 
Criterion 
(BIC) 
3562   3066    
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